Clivatuzumab
CAS No. 1622075-09-5
Clivatuzumab( —— )
Catalog No. M36841 CAS No. 1622075-09-5
Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 347 | Get Quote |
|
| 5MG | 598 | Get Quote |
|
| 10MG | 943 | Get Quote |
|
| 25MG | 1352 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameClivatuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionClivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.
-
DescriptionClivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1622075-09-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Gold DV, et al. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer. 2013 Nov 20;12(1):143. ?
molnova catalog
related products
-
Pyruvic acid
Pyruvic acid is an intermediate compound in the metabolism of carbohydrates proteins and fats. In thiamine deficiency its oxidation is retarded and it accumulates in the tissues especially in nervous structures.
-
TFEB activator 1
TFEB activator 1 is an activator?of transcription factor EB (TFEB) ?with promise for the prevention or treatment of Alzheimer's disease.
-
GSK2256294A
GSK2256294A is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.
Cart
sales@molnova.com